| 168.92 |  -0.63 / -0.37% |
Data as of 4:04pm ET | Day’s Change |
| 169.17 |  +0.25 / +0.15% |
Volume: 4.6K |
| Positive Data on Novo Nordisk's N9-GP - Analyst Blog May 21 / Zacks.com |
| Previous close | 169.55 |
| Today’s open | 168.97 |
| Day’s range | 167.69 - 169.63 |
| Volume | 237,213 |
| Average volume (3 months) | 283,528 |
| Market cap | $73.2B |
| Dividend yield | 1.88% |
| Earnings growth (last year) | +19.33% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +14.00% |
| Revenue growth (last year) | +8.57% |
| P/E ratio | -- |
| Price/Sales | 6.61 |
| Price/Book | 12.81 |
| Today’s change | Today’s % change | |
|---|---|---|
| ABBVAbbVie Inc | -0.17 | -0.36% |
| BMYBristol-Myers Squibb... | +0.60 | +1.29% |
| AZNAstraZeneca PLC | -0.27 | -0.52% |
| LLYEli Lilly and Co | -0.18 | -0.33% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | $2.11 |
| Annual revenue (last year) | $13.5B |
| Annual profit (last year) | $3.7B |
| Net profit margin | 27.47% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
President & Chief Executive Officer Lars Rebien Sørensen |
Chief Operating Officer & Executive Vice President Kåre Schultz |
Corporate headquarters Bagsværd, -- |
.
